The FDA placed the clinical hold on two phase 2 studies of zelnecirnon, which was being tested for eczema and asthma. The serious adverse event happened in a participant of the eczema trial.
RAPT said the cause is unknown but “has been characterized as potentially related to zelnecirnon,” according to a news release. Enrollment of new participants and administration of the drug has been halted in both clinical trials.
About 350 patients have been enrolled in RAPT’s trials for zelnecirnon, and liver toxicity has not been observed with anyone else. The company said it is investigating the matter.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.